ライフサイエンスコーパス: neuroendocrine carcinoma

1 l carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma.

2 all cell lung cancer (SCLC) is a devastating neuroendocrine carcinoma.

3 num plus etoposide for those with large-cell neuroendocrine carcinoma.

4 nts with liver metastases from colorectal or neuroendocrine carcinoma.

5 YCN in cells of the pancreatic islet induces neuroendocrine carcinoma.

6 t predictors of poor prognosis in esophageal neuroendocrine carcinoma.

7 mixture of pure-SCLC (P-SCLC) and large cell neuroendocrine carcinoma.

8 small cell lung cancer (SCLC) and high-grade neuroendocrine carcinomas.

9 sistant cancers to the aggressive small cell neuroendocrine carcinomas.

10 of the rapid development and progression of neuroendocrine carcinomas.

11 al carcinoids from small-cell and large-cell neuroendocrine carcinomas.

12 nsdifferentiate certain adenocarcinomas into neuroendocrine carcinomas.

13 with infantile myofibromatosis, 1 of 2 with neuroendocrine carcinomas, 1 of 2 with pancreaticoblasto

14 olated from 29 epithelial ovarian cancers, 1 neuroendocrine carcinoma, 3 mixed mesodermal tumors, and

15 Primary tumor histology included neuroendocrine carcinoma (34.9%), pancreatic ductal aden

16 ase), colonic adenocarcinoma (5 of 5 cases), neuroendocrine carcinoma (5 of 5 cases), glioblastoma mu

17 Eighteen (82%) had cancer: neuroendocrine carcinomas (9; pancreatic (3), small-cell

18 l-cell lung cancer and eight with large-cell neuroendocrine carcinoma, all of whom received at least

19 etastases from other primary tumors, such as neuroendocrine carcinoma and genitourinary tumors, are a

20 get genes common between prostate small cell neuroendocrine carcinoma and primary prostate basal cell

21 -grade neuroendocrine carcinomas: large cell neuroendocrine carcinomas and small cell carcinomas.

22 Poorly differentiated anal neuroendocrine carcinomas (ANECs) are rare lesions with

23 However, neuroendocrine carcinomas are becoming more common becau

24 Thus, neuroendocrine carcinomas are the principal malignancy i

25 s using TRAMP prostatic ducts suggested that neuroendocrine carcinomas arise independently from atypi

26 oma, squamous cell carcinoma, and large-cell neuroendocrine carcinoma, but not small-cell carcinoma o

27 versus 12.1% in DGCs), as were mucinous and neuroendocrine carcinomas, carcinoma with lymphoid strom

28 nmetastatic poorly differentiated colorectal neuroendocrine carcinomas (CRNECs) following resection.

29 In human esophageal neuroendocrine carcinoma (eNEC) cells, p63 is transcript

30 Patients with extrapulmonary neuroendocrine carcinomas (EPNECs) receive essentially t

31 contrast, all 40 small-cell and 6 large-cell neuroendocrine carcinomas failed to show RB staining in

32 Gastric neuroendocrine carcinomas (G-NEC) are aggressive maligna

33 to serve as a biomarker for high-grade lung neuroendocrine carcinomas; however, its functional roles

34 herapy cohort among patients with left-sided neuroendocrine carcinomas (HR, 0.55; 95% CI, 0.44-0.68),

35 ng AC in patients with poorly differentiated neuroendocrine carcinomas in the colon and rectum.

36 to deliver a systematic review of esophageal neuroendocrine carcinoma, including patient characterist

37 ical carcinoid tumours as well as high-grade neuroendocrine carcinomas: large cell neuroendocrine car

38 aggressive malignancies, such as large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung can

39 Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive l

40 id (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell lung ca

41 noids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lun

42 D1-SCLC characterized by distinct large-cell neuroendocrine carcinoma-like histopathology.

43 for small cell or mixed small and large cell neuroendocrine carcinoma (n = 7), solid attenuation (n =

44 differentiation of NEN in the direction of a neuroendocrine carcinoma (NEC - neuroednocrine carcinoma

45 a of the pancreas (SCCP) is a rare malignant neuroendocrine carcinoma (NEC).

46 rstood to be intermediate between NET G2 and neuroendocrine carcinoma (NEC).

47 (8.3%) atypical NET, 998 (22.3%) large cell neuroendocrine carcinoma (NEC, including small cell and

48 Neuroendocrine carcinomas (NEC) are tumors expressing ma

49 a GNET Type 3: 1 well-differentiated NET G3, neuroendocrine carcinomas (NECs) (n = 3), and controls (

50 poorly differentiated and highly aggressive neuroendocrine carcinomas (NECs), including small-cell l

51 ere diagnosed (Hodgkin's disease; metastatic neuroendocrine carcinoma; non-small cell lung cancer).

52 Neuroendocrine carcinoma of the esophagus is a highly ag

53 carcinoma (MCC) is an aggressive, HLA-I-low, neuroendocrine carcinoma of the skin often caused by the

54 Merkel cell carcinoma is a rare neuroendocrine carcinoma of the skin which shares severa

55 in the chlorambucil plus obinutuzumab group (neuroendocrine carcinoma of the skin).

56 eptibility of Merkel cell carcinoma (MCC), a neuroendocrine carcinoma of the skin, to inhibitors of t

57 cell carcinomas (MCCs), a highly aggressive neuroendocrine carcinoma of the skin.

58 n-small-cell lung cancer (NSCLC), high-grade neuroendocrine carcinomas of the lung often only have a

59 carcinoma in situ (one child), and tracheal neuroendocrine carcinoma (one child).

60 Neuroendocrine carcinoma patients had a lower death rate

61 s with EGFR-mutant SCLC and other high-grade neuroendocrine carcinomas seen at our eight institutions

62 h a zebrafish transgenic model of pancreatic neuroendocrine carcinoma, setting the stage to evaluate

63 Treatment for advanced poorly differentiated neuroendocrine carcinoma should parallel treatments used

64 l carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma that is classified as Merkel ce

65 nocarcinoma (PDA), 21; poorly differentiated neuroendocrine carcinoma, three; and squamous carcinoma,

66 e four small cell carcinomas, two large cell neuroendocrine carcinomas, two adenosquamous carcinomas,

67 e cancer revealed that metastatic small cell neuroendocrine carcinoma was molecularly more stem-like

68 zing poorly differentiated tumors, including neuroendocrine carcinomas, were developed and are discus

69 care for a 71-year-old woman with metastatic neuroendocrine carcinoma who has a short life expectancy

70 mall cell lung cancer (SCLC) is a high-grade neuroendocrine carcinoma with an incidence of 4.7 cases

71 toxicity in small-cell lung cancer (SCLC), a neuroendocrine carcinoma with high mortality and modest

72 C) is a rare and highly aggressive cutaneous neuroendocrine carcinoma with increasing incidence.